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Zoltán Kele b, Tamás Gajda a,* 
a Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary 
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A B S T R A C T   
Our goal was to explore the possible interactions of the potential metallodrug (η5-Cp*)Rh(III) complexes with 
histidine containing biomolecules (peptides/proteins) in order to understand the most important thermodynamic 
factors influencing the biospeciation and biotransformation of (η5-Cp*)Rh(III) complexes. To this end, here we 
report systematic solution thermodynamic and solution structural study on the interaction of (η5-Cp*)Rh(III) 
cation with histidine containing peptides and their constituents ((N-methyl)imidazole, GGA-OH, GGH-OH, 
histidine-amide, HGG-OH, GHG-NH2), based on extensive 1H NMR, ESI-MS and potentiometric investigations. 
The comparative evaluation of our data indicated that (η5-Cp*)Rh(III) cation is able to induce the deprotonation 
of amide nitrogen well below pH 7. Consequently, at physiological pH the peptides are coordinated to Rh(III) by 
tridentate manner, with the participation of amide nitrogen. At pH 7.4 the (η5-Cp*)Rh(III) binding affinity of 
peptides follow the order GGA-OH < < GGH-OH < < histidine-amide < HGG-OH < GHG-NH2, i.e. the observed 
binding strength essentially depends on the presence and position of histidine within the peptide sequence. We 
also performed computational study on the possible solution structures of complexes present at near physio-
logical pH. At pH 7.4 all histidine containing peptides form ternary complexes with strongly coordinating (N,N) 
bidentate ligands (ethylenediamine or bipyridyl), in which the peptides are monodentately coordinated to Rh(III) 
through their imidazole N1‑nitrogens. In addition, the strongest chelators histidine-amide, HGG-OH and GHG- 
NH2 are also able to displace these powerful bidentate ligands from the coordination sphere of Rh(III).   
1. Introduction 
Due to their unique chemical properties, a number of half-sandwich 
organometallic compounds of transition metal ions with low spin d6 
electron configuration (Ru(II), Os(II), Rh(III), Ir(III)) have promising 
activity in various diseases, e.g. possess significant anticancer activity, 
even against cancers that are not responsive to platinum drugs [1–5]. 
Following the work made in the Sadler and Dyson research groups, a 
number of further (arene)Ru(II)-based compounds have been identified 
as potential candidates for clinical development [1–7]. Although, 
considerably less experimental data have been published for the 
isoelectronic (arene)Rh(III) compounds, several (η5-Cp*)Rh(III) com-
plexes exhibit higher in vitro activity than the related Ru(II) complexes 
or even cisplatin, at least against selected cancer cell lines [8–17]. In 
addition, its optimal ligand exchange kinetics make (η5-Cp*)Rh(III) 
cation suitable drug delivery system for cytotoxins that are too toxic to 
be delivered directly, or have poor pharmacokinetics, such as curcumin 
[18]. 
These Ru/Rh-based compounds can act using both DNA or enzymes 
as target, but their molecular mechanisms of action have not yet been 
fully elucidated [1–7,19]. On the other hand, even DNA targeting 
compounds may interact with peptides/proteins during drug-transport, 
e.g. may undergo ligand substitution reactions especially in the blood 
plasma, before they reach the target site. It is therefore of high interest to 
study reactions between potential metallodrugs and biomolecules in 
order to understand their biodistribution, biotransformation and phar-
macokinetic properties. 
Increasing number of structural (MS/NMR [20–25], crystallographic 
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[26–32]) studies are available on the protein binding of [(arene)M(ab)c] 
compounds (where M = Ru(II), Rh(III); ab and c stand for bidentate and 
monodentate ligands, respectively). Since, different proteins under 
different conditions (pH, incubation time, ionic strength etc.) were 
studied, the reported data show rather promiscuous binding of (arene) 
Ru(II)/Rh(III) cations. Mainly His, Met, Cys and/or Glu sidechains are 
involved, and the proteins may coordinate by mono-, bi- and even tri-
dentate manner. The latter indicates extensive degradation of [(arene)M 
(ab)c] complexes, even the arene ring can be lost [26]. Recently, the 
interaction of several (arene)Ru(II)/Rh(III) complexes with human 
serum albumin (HSA) has been studied [33]. HSA binds to 24 ± 3 
uncomplexed (Cp*)Rh(III) cations, among them 8 were assumed to be 
amide coordinated, i.e. chelated by {Nim,N− amide} donors, but direct 
evidence of this binding mode was not obtained. 
In order to understand the protein binding of (arene)Ru(II)/Rh(III) 
cations in more details amino acid and peptide complexes were also 
investigated. The [(arene)Mc3] (c = H2O or Cl− ) species form the usual 
mononuclear bi- and tridentate complexes with amino acids [34–37], 
while cysteine and penicillamine may form dinuclear complexes, too 
[38]. However, the interaction of amino acids with [(arene)M(ab)c] 
complexes strongly depends on the nature the bidentate ab ligands. For 
example, the [(η6-biphenyl)Ru(en)Cl]+ cation reacts slowly with amino 
acids, and the order of reactivity is Cys > Met > His [20]. In contrast, 
(η5-Cp*)Rh(III) and (η6-p-cymene)Ru(II) complexes of flavanol de-
rivatives show clear reactivity preference for His [13,25] (and Met [25]) 
over Cys. 
Peptides behave similarly to proteins, the putative amino acid resi-
dues involved in the coordination are His [39,40], Met [40] and Cys 
[41], if available, with additional binding to Asp/Glu [20,40], and 
interestingly, the nitrogen atoms of the backbone amides were also 
hypothesized [21,40]. Several crystal structures of (Cp*)Rh(III) and (η6- 
C6Me6)Ru(II) peptide complexes have been reported which include co-
ordinated amide nitrogen(s) [34,42]. Since half-sandwich cations have 
only facial coordination sites, the central deprotonated amide nitrogen 
in {NH2,N− ,N− } coordinated complexes is severely distorted towards a 
pyramidal conformation [42]. The solution structural study on [(η6-p- 
cymene)Ru(II)]2+ complexes of His-peptides revealed histamine-like 
binding mode (HAVAHHH-NH2 [43]) or {3Nim} coordination (Ac- 
HAHH-NH2, Ac-HAHAH-NH2 [44]) in the physiologically relevant pH 
range, but amide coordination was not observed. Interestingly, the ar-
omatic side chain of tyrosine can also interact with (η5-Cp*)Rh(III) 
cation in water at pH 5–6 [45]. 
Solution thermodynamic data on peptide complexes of (arene)Ru 
(II)/Rh(III) cations are extremely rare in the literature. An indicator- 
displacement assay for the sequence-selective detection of His/Met- 
containing peptides has been developed [46] based on the different 
binding affinity of (η5-Cp*)Rh(III) cation to peptides with different se-
quences, but only relative and apparent binding constants were re-
ported. Besides, only (arene)Ru(II)/Rh(III) complexes of peptido- 
hydroxamic acids have been studied from solution thermodynamic 
point of view [47]. 
Our goal was to explore the possible interactions of potential met-
allodrug (η5-Cp*)Rh(III) complexes with biomolecules (peptides/pro-
teins), in order to understand the thermodynamic factors influencing the 
binding of (arene)Ru(II)/Rh(III) cations to peptides/proteins in aqueous 
solutions, as well as to investigate the possibility of amide coordination 
assumed by earlier studies [21,33,40]. As the imidazole ring of histidine 
side-chains is one of the main binding sites for (arene)Ru(II)/Rh(III) 
cations in proteines, first we performed systematic solution thermody-
namic, solution structural and computational study on the binary com-
plexes of (η5-Cp*)Rh(III) cation with histidine containing peptides and 
their constituents ((N-methyl)imidazole (L1(m)), GGA-OH (L2), GGH-OH 
(L3), histidine-amide (L4), HGG-OH (L5), and GHG-NH2 (L6), see Scheme 
1). The primary reason for the selection of ligands was to study the 
coordination ability of imidazole ring to (η5-Cp*)Rh(III) in different 
donor environments. Having explored the binary (η5-Cp*)Rh(III)-pep-
tide complexes, we also studied some (η5-Cp*)Rh(III)-A-B ternary sys-
tems (where A = L2, L3, L4, L5 or L6 and B = 2,2′-bipyridyl or 
ethylenediamine) in order to mimic the interaction of the (η5-Cp*)Rh 
(III)-based potentially anticancer or drug delivery agents with proteins. 
Although, the solution speciation of (η5-Cp*)Rh(III) and (η6-p-cymene) 
Ru(II) complexes show some differences due to their different hydrolytic 
properties [47], we believe that our results give valuable hints con-
cerning the interaction of the extensively studied potentially anticancer 
Scheme 1. Schematic structures of the studied ligands (the numbering of imidazole ring is shown for L4)  
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half-sandwich Ru(II) complexes with biomolecules, too. 
2. Results and discussion 
The pK values of the studied ligands (Table 1) agree very well with 
earlier reports [48]. In the following, the different systems are presented 
separately, the solution thermodynamic and solution structural prop-
erties of major complexes are discussed parallel, in the order of their 
appearance in solution with increasing pH. 
2.1. Interaction of (η5-Cp*)Rh(III) with imidazole (L1) and N- 
methylimidazole (L1m) 
The monodentate imidazol coordination is the most frequently 
detected binding mode of proteins to half-sandwich Ru(II)/Rh(III) 
complexes [23,26,29–33]. Indeed, (η5-Cp*)Rh(III) forms rather stable 
[ML1(m)]2+, [ML1(m)2]2+ and [ML1(m)3]2+ complexes (here and in the 
following M stands for (η5-Cp*)Rh(III) cation) up to the neutral pH range 
(Table 1, Fig. S1, see Supplementary Material). The formation constants 
of these parent complexes are nearly identical for the two ligands, and 
indicate somewhat lower stability than those of the related (η6-p-cym-
ene)Ru(II)-L1m complexes [49]. Since Rh(III) is diamagnetic (low spin d6 
cation) in all our complexes, NMR is a straightforward method to gain 
information on the solution structure and also to support the solution 
speciation. Indeed, all L1(m) complexes have slow exchange on the NMR 
timescale, and thus the changes in speciation can be easily followed 
(Fig. S2). Interestingly, in the (η5-Cp*)Rh(III)-L1 system between pH 4–6 
a broad signal appeared at 12 ppm (see the discussion on this signal 
below). Above pH 7–8 the two systems behave rather differently. In the 
(η5-Cp*)Rh(III)-L1m system the complex formation processes are fast 
enough for equilibrium study. In alkaline solution, a single additional 
species, [MH− 1L1m2]+ (= [M(OH)L1m2]+) could be detected. On the 
other hand, in the (η5-Cp*)Rh(III)-L1 system the time needed to reach 
the equilibrium considerably increased above pH 7, which prevented the 
correct equilibrium study. After 24 h of equilibration at pH > 7 the 1H 
NMR spectra indicate the formation of a great number of isomers 
(Fig. S2). Considering the difference between the two ligands, the most 
plausible reason of isomer formation is the metal-promoted deproto-
nation of the non-coordinated imidazole N1H group of L1, and the 
subsequent formation of different oligomers via imidazolato bridges. 
The crystal structure of an imidazolato-bridged (η5-Cp*)Rh(III) complex 
has been already reported in the literature [50]. 
2.2. Interaction of (η5-Cp*)Rh(III) with GGA-OH (L2) 
In order to assess the effect of histidine moiety of tripeptides on (η5- 
Cp*)Rh(III) binding, first we studied the complexes of GGA-OH peptide, 
having no coordinating side-chain. The combined potentiometric, 
UV–Vis and NMR results revealed the formation of four species between 
pH = 2–11 (Table 1, Fig. 1). The formation constants obtained reflect 
surprisingly high (η5-Cp*)Rh(III) binding affinity of this simple peptide 
in the physiological pH range. The (η5-Cp*)Rh(III) promoted deproto-
nation of N-terminal ammonium group takes places at four units lower 
pH than in the free ligand, confirming its strong binding to the metal ion. 
The important low field shift of 2G-NH proton signal (8.55 → 9.22 ppm, 
see Fig. S3) in [ML2]+ suggests the formation of {NH2,C=O,Cl− } donor 
set, with the participation of 1G amide oxygen. The next species ([ML2]+
= [MH− 1L2] + H+, pK = 5.80) is dominant in the solution between pH 
7–9. Parallel with its formation the signal of 2G amide disappeared from 
the spectrum (see Fig. S3), indicating its metal-promoted deprotonation, 
since the signal of 3A amide is still present at pH 7.3. To our knowledge 
this is the first reported pK for amide nitrogen deprotonation of simple 
peptides promoted by a half-sandwich cation. The only related values, 
which have been determined for (η5-Cp*)Rh(III) complexes of peptido- 
hydroxamic acids [47], indicate similar pH range for (η5-Cp*)Rh(III)- 
promoted amide deprotonation. 
On the TOCSY (TOtal Correlation SpectroscopY) spectrum of 
[MH− 1L2] new peaks appeared around 4.45 ppm, which resulted strong 
cross-peaks with the 1G-CH2 proton signals (Fig. S4). Consequently, this 
new peaks belong to the terminal amino group, i.e. its proton-exchange 
with the solvent slows down considerably upon coordination. The 
Table 1 
Protonation constants of the studied ligands, formation constants of their (η5-Cp*)Rh(III) complexes and some derived data (T = 298 K, I = 0.20 M (KCl)), with 
estimated errors in parentheses (last digit). The constants in square brackets are only indicative values, since the systems were non-equilibrated.   
log βpqr 
species (pqr) L1 L1m L2 L3 L4 L5 L6 
H3L (031) – – – 17.45(2) – 16.17(7) – 
H2L (021) – – 11.25(2) 14.80(1) 12.90(1) 12.89(3) 14.50(2) 
HL (011) 7.02(1) 7.10 (1) 7.98(1) 8.00(1) 7.48(1) 7.42(1) 8.23(1) 
MHL (111) – – 10.63(8) 13.92(5)  14.88(1) 13.98(8) 
ML (101) 5.83(2) 5.94(2) 6.68(3) 9.72(3) 11.09(5) 11.38(1) – 
ML2 (102) 10.46(2) 10.68(2) – – – – – 
ML3 (103) 13.43(3) 13.64(3) – – – – – 
MH− 1L (1− 11) – – 0.88(3) 2.75(4) 5.04(5) 5.89(11) 7.04(4) 
MH− 2L (1− 21) [− 10.2]  − 9.74(3) [− 8.1] [− 5.2] [− 4.6] [− 2.8] 
MH− 1 L2 (1− 12) [2.6] 0.39(4) – – – – – 
pKNH, amide – – 5.80 6.97 6.05 5.49 ~ 3.5 
pM*7.4 6.82 6.89 8.57 10.47 13.07 13.94 14.48 
pM* values at pH 7.4 and at cM = cL/10 = 1 μM (T = 25 ◦C; I = 0.20 M (KCl), where pM* = − log([M] + 2[M2(OH)2] + 2[M2(OH)3]). 
Fig. 1. Speciation in the (η5-Cp*)Rh(III)-GGA-OH (L2, red lines) and (η5-Cp*) 
Rh(III)-GGH-OH (L3, blue dashed lines) 1/1 systems (T = 298 K, I = 0.2 M KCl, 
[M]tot = 0.001 M). The curves of uncomplexed metal ion are not shown for 
clarity. In the case of GGH-OH the curve marked as ‘MH− 1L’ represents the sum 
of [MH− 1L3] and [MH− 1L3]2 complexes (see chapter 2.3.). Dotted lines show 
the region of slow processes, where only approximate speciation can be given. 
(For interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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NOESY (Nuclear Overhauser Effect SpectroscopY) spectrum of 
[MH− 1L2] revealed cross-peaks between the Cp*-CH3 and 1G-CH2, 2G- 
CH2 protons, confirming the coordination of 1G-amino and 2G-amide 
nitrogens. On the other hand, the coordination of C-terminal carboxylate 
is not supported by our experimental data, i.e. the metal ion is coordi-
nated by a {NH2,N− ,Cl− } donor set. 
Above pH 9 a further deprotonation was observed (pK = 10.62). 
During this process new set of peaks were not developed, only those of 
[MH− 1L2] were shifted, indicating a fast-exchanging deprotonation. 
Although, the signal of 3A amide proton disappeared from the spectra 
above pH 8, it is due to the acceleration of its proton exchange with the 
bulk water, since the coordination of this amide nitrogen would result in 
the development of a new set of peaks. The most obvious explanation of 
this process is the formation of mixed hydroxido complex, i.e. the {NH2, 
N− ,OH− } coordinated [MH− 2L2]− species. 
To assess the strength of (η5-Cp*)Rh(III)-L2 interaction, it is worth 
examining the predominance diagram of the (η5-Cp*)Rh(III)-Cu(II)-L2 
ternary system (Fig. S5). In the physiological pH range the peptide is 
dominantly coordinated to (η5-Cp*)Rh(III), i.e. its interaction with L2 is 
much stronger than that of the well-known peptide binder copper(II). 
2.3. Interaction of (η5-Cp*)Rh(III) with GGH-OH (L3) 
GGH-OH is an analogue of the N-terminal copper and nickel binding 
site of human serum albumin. Between pH 3–6 four distinct signals of 
Cp*-methyl protons can be detected on the 1H NMR spectra (Fig. S6), 
two of which belong to [MHL3]2+. This indicates the formation of iso-
mers of this complex, either diastereomers or binding isomers. Surpris-
ingly, two broad signals also appeared at 12.0 and 12.3 ppm on the 1H 
NMR spectra (Fig. S6) up to pH 6 in 90% H2O – 10% D2O solution, which 
were absent in 100% D2O. Similar signals were detected in the acidic 
pH-range for all imidazole derivatives, except for N-methylimidazole, 
and can be assigned to the N1H proton of coordinated imidazole ring, 
whose proton exchange slowed down significantly due to the metal 
coordination of N3‑nitrogen. In the present case, the two signals belong 
to [MHL3]2+ (12.0 ppm) and [ML3]+ (12.3 ppm) complexes. Parallel 
with the formation of [ML3]+ the signal of 2G-NH is considerably shifted 
as compared to the free ligand (8.45 → 9.55 ppm, Fig. S6). The TOCSY 
spectrum observed at pH 5.6 indicates unusually high – approximately 
400 Hz - inequivalence for the 1G and 3H methylene-protons (Fig. 2), 
which is likely due to the involvement of these methylene groups in 
rather rigid fused chelate ring(s). Remarkably, two peaks at 5.00 and 
5.33 ppm are also appeared on the TOCSY spectrum resulting strong 
cross-peaks with the 1G methylene-protons (Fig. 2), which therefore 
belong to the Rh(III) coordinated terminal amino group. Based on the 
NOESY spectrum, of the two imidazole CH protons, only C2H is close to 
the Cp* methyl protons (Fig. S7). Besides, spatial proximity has been 
detected between Cp*-CH3 and 3H-CβH2, as well as between 3H-C5H and 
1G-NH2 protons (Fig. S7). All these facts indicate tridentate {NH2,C=O, 
N3im} type coordination in [ML3]+. Indeed, [ML3]+ has considerably 
higher thermodynamic stability as compared to [ML2]+ (log β101 = 6.68 
and 9.71 for L2 and L3, respectively), due to the additional imidazole 
coordination. 
In turn, the enhanced stability of tridentate coordination in ML3 
results in markedly higher pK for the next deprotonation ([ML]+ =
[MH− 1L] + H+, pKML = 5.80 (L2) and 6.98 (L3), see Fig. 1). During this 
process the amide proton signal of 2G disappeared from the 1H NMR 
spectra (Fig. S6). Since the 3H amide signals were still detectable, the Rh 
(III) promoted deprotonation of 2G amide took place during this process. 
Interestingly, the deprotonation resulted in the duplication of signals, i. 
e. the formation of two isomers with nearly equal concentrations. 
The EXSY (EXchange SpectroscopY) spectrum measured at pH 9.2 
reflects that these isomers are in conformational or chemical exchange 
(Fig. 3A), i.e. are not diastereoisomers. The mass spectrum detected 
under identical conditions indicates the presence of a monomer and a 
dimer species in nearly equal amount (Fig. S8A), thus the exchange is 
related to the 2[MH− 1L3] = [MH− 1L3]2 equilibrium. The pH-metric 
titration curves can be well fitted by either the monomer or the dimer 
species, but the parallel refinement of β1–11 and β2–22 is not possible. 
However, assuming equal concentration of the monomer and dimer 
logβ1–11 ~ 2.6 and logβ2–22 ~ 8.6 can be estimated. Based on the NOESY 
spectrum, both CH protons of the imidazole ring (C2H and C5H) of both 
Fig. 2. Part of TOCSY spectrum of the (η5-Cp*)Rh(III)-L3 1:1 system at pH 5.67.  
Fig. 3. Parts of EXSY (A) and TOCSY (B) spectra of the (η5-Cp*)Rh(III)-L3 1:1 
system at pH 9.35. 
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complexes are in spatial proximity to the Cp* methyl protons (Fig. S8B). 
This is only possible if the N1 nitrogen of imidazole ring is coordinated to 
Rh(III). In addition, the 1G-CH2 protons are also close to the Cp* methyl 
protons, suggesting {NH2,N− ,N1im} type coordination in both species. In 
one of these complexes the histidine CβH2 protons are slightly, in the 
other they are considerably inequivalent (Fig. 3B). In the monomer 
complex the imidazole group is part of a 10-membered, rather strained 
macrochelate ring (Fig. 4A), and its reduced chelate effect allows the 
formation of dimer species. In [MH− 1L3]2 the imidazole rings bind to the 
adjacent (η5-Cp*)Rh(III), resulting in a more relaxed conformation of the 
histidine side chains (Fig. S18), thus the dimer has probably the more 
equivalent histidine CβH2 protons (signals marked by ‘a’ in Fig. 3). 
Above pH 8 a further deprotonation was detected (pK ~ 11), but the 
complex formation processes become too slow for equilibrium study. At 
pH 11.6 at least nine peaks appeared in the region of Cp* methyl protons 
(Fig. S6), indicating the formation of several isomers, but structural 
details could not be extracted. 
2.4. Interaction of (η5-Cp*)Rh(III) with histidine-amide (L4) and HGG- 
OH (L5) 
Both ligands are simple model of N-terminal histidine unit in pro-
teins. In the (η5-Cp*)Rh(III)-L4 system three complexes can be identified 
between pH 2–12 (Table 1, Fig. 5). The broad signal related to the N1H 
proton of coordinated imidazole ring appeared on the 1H NMR spectra 
between pH 2–6 in this case, too (Fig. 6A). The formation constant of 
[ML4]2+ complex is much higher than the analogous values of [ML1]2+, 
[ML2]+ or [ML3]+, indicating the coordination of both N3im and amino 
nitrogens within a 6-membered chelate. Since the resonances of amide 
protons did not change between pH 2–4, the coordination of carbonyl 
oxygen is unlikely. Therefore the metal ion in [ML4]2+ has {NH2,N3im, 
Cl− } donor set, with bidentate, histamine-like coordination of L4. 
Above pH 4 a new set of peaks developed on the 1H NMR spectra 
(Fig. 6A), belonging to the [MH− 1L4]+ species (pK = 6.05). As in the 
previous cases, new signals appeared on the 1H NMR spectra close to the 
water resonance. In fact, the signal closest to water (at 4.90 ppm) is 
obscured and only its cross peaks appeared on the 2D spectra (Fig. 6B). 
The peaks at 4.90 and 5.15 ppm show spatial proximity to the Cα-H 
proton (Fig. S9A), thus belong to the coordinated amino-NH2, while the 
resonance at 5.53 ppm is related to the deprotonated (and coordinated) 
amide-NH− . The coordination of these nitrogens is further supported by 
the spatial proximity of their protons to the Cp*-methyl protons 
(Fig. S9). On the other hand, among the two imidazole CH protons, only 
C2H shows vicinity to the Cp*-ring, which clearly indicates {N3im,NH2, 
NH− } binding mode in [MH− 1L4]+ (Fig. 4B). 
The (η5-Cp*)Rh(III)-L5 system behaves analogously. The formation 
Fig. 4. Optimized structures of the RRhSαC diastereomers of MH− 1L3 (A), 
MH− 1L4 (B), MH− 1L5 (C) and MH− 1L6 (D). See chapter 2.7. 
Fig. 5. Speciation in the (η5-Cp*)Rh(III)-L4 (blue dashed lines) and (η5-Cp*)Rh 
(III)-L5 (red lines) 1/1 systems (T = 298 K, I = 0.2 M KCl, [M]tot = 0.001 M). 
The curves of uncomplexed metal ion are not shown for clarity. Dotted lines 
indicate the region of slow processes, where only approximate speciation can be 
given. (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) 
Fig. 6. Parts of pH-dependent 1H NMR spectra (A) and TOCSY spectrum at pH 
8.55 (B) of (η5-Cp*)Rh(III)-L4 2/3 system (asterix denotes the signals of the 
free ligand). 
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constants of [ML4]2+ and [ML5]+ complexes are very similar, and the 
imidazole N1H proton appeared on the 1H NMR spectra of both 
[MHL5]2+ and [ML5]+ (Fig. S10A), confirming the coordination of N3 
nitrogen in these species. The pK of [MHL5]2+ (pK = 3.50) is close to the 
pK of carboxylate in the free ligand (Table 1). Consequently, in both 
[MHL5]2+ and [ML5]+ the ligand binds to the metal ion with histamine- 
like {NH2,N3im} coordination, they differ only in the protonation state of 
the C-terminal carboxylate, remote from the metal ion. 
During the deprotonation of [ML5]+ species (pK = 5.49) the signal of 
2G amide proton disappeared from the 1H NMR spectrum. Like in the 
previous cases, parallel with this amide deprotonation new signals 
appear near the water, which show strong TOCSY cross-peaks with 
histidine C5H, CαH and CβH2 protons, and therefore belong to the co-
ordinated N-terminal amino group (Fig. S10B). Among the two imid-
azole CH protons, only the C2H proton exhibits spatial proximity to the 
Cp* methyl protons, thus the N3 nitrogen of the imidazole ring is coor-
dinated in MH− 1L5. Besides, the 1H-NH2, 2G-CH2 and 3G-NH protons are 
also close to the Cp* ring (Fig. S9B), confirming the Rh(III)-promoted 
deprotonation of 2G amide, and therefore the {N3im,NH2,N− } binding 
mode in MH− 1L5 (Fig. 4C). 
Above pH 8 a further deprotonation was observed in both systems, 
leading to MH− 2L in slow processes. During these deprotonations new 
set of peaks did not appear, only those already present were shifted 
(Figs. 6A and S10), i.e. this deprotonation does not alter the coordina-
tion sphere of Rh(III). Two of such processes may take place, the 
deprotonation of the amino or imidazole N1‑nitrogens. Since the imid-
azole C2H and C5H protons show the largest shift between pH 8–12, and 
the signals of coordinated amino group are less affected, this deproto-
nation is probably related (at least for the most part) to the imidazole 
N1‑nitrogen. 
2.5. Interaction of (η5-Cp*)Rh(III) with GHG-NH2 (L6) 
In this peptide the histidine is in the second position, and since it was 
prepared in our laboratory, the C-terminal carboxylate is amidated. 
After the formation of a minor species [MHL6]3+ between pH 2–4, two 
strongly cooperative deprotonations have been detected. Consequently, 
the formation of [ML6]2+ could not be observed, only that of the sub-
sequent [MH− 1L6]+ complex (Fig. S11), which is the only species in the 
solution between pH 4.5–8. Up to pH 4.43 the 2H amide proton gradu-
ally disappeared, while the signals of terminal (1G) NH2 and imidazole 
N1H protons appeared on the NMR spectra (Figs. 7 and S12). The NOESY 
spectrum indicates spatial proximity between the Cp*-methyl and 
imidazole C2H, 3G amide (Fig. 7B), 1G-NH2, 1G-CH2 as well as 2H-CβH2 
protons (Fig. S13). All these facts confirm the {NH2,N− ,N3im} type co-
ordination of peptide in [MH− 1L6]+ species. This is somewhat surprising 
considering that L6 in this binding mode prefers meridional, while (η5- 
Cp*)Rh(III) prefers facial coordination. Therefore, we suspected dimer 
formation, similar to the case of GGH-OH (L3). However, the MS spec-
trum at pH 5 clearly indicates the sole presence of the monomer 
[MH− 1L6]+ complex (Fig. S14). The crystal structures of tridentate 
{NH2,N− ,N− } coordinated (Cp*)Rh(III)-peptide complexes indicate that 
the central deprotonated amide nitrogen is distorted towards a pyra-
midal conformation [42]. Probably, the high thermodynamic stability 
over-compensates this conformational strain. Indeed, the potentiometric 
data show outstanding stability of the amide-coordinated complex of L6, 
its formation takes place at 3–4 units lower pH than in the former 
systems. 
Interestingly, in the (η5-Cp*)Rh(III)-L6 system a minor diastereomer 
(RRhSαC or SRhSαC) also appeared beside the major one. This resulted in 
the duplication of signals, which can be clearly seen e.g. on the imid-
azole CH and Cp*-methyl signals (see Fig. S12 and further discussion on 
the diastereomers in chapter 2.7.). 
In this system, too, an additional deprotonation was observed above 
pH 8, which process was proved to be very slow, the equilibrium was not 
reached even after several days. In this case, however, the slow complex 
formation process was further complicated by the slow hydrolysis of the 
C-terminal amide group, which can be clearly seen on the time depen-
dent MS spectrum at pH 11.04 (Fig. S15). This hydrolysis is obviously 
related to the coordinated metal ion, but the exact mechanism is 
unknown. 
2.6. Comparison of equilibrium data and competition with strongly 
coordinating bidentate ligands 
Due to the different basicity of the ligands and composition of their 
complexes, it is more appropriate to calculate the concentration of non- 
peptide bound metal ion (pM* = − log([M] + 2[M2(OH)2] + 2 
[M2(OH)3]) at pH 7.4 and at 10 × [M]tot = [L]tot = 10− 5 M, in order to 
compare the metal ion binding abilities of the studied ligands (Table 1). 
Obviously, the monodentate L1 and L1m have the lowest metal binding 
affinity, which are followed by GGA-OH (L2). The coordination ability of 
histidine containing peptides strongly depends on the position of His 
unit. Such dependency has already been identified for copper(II) com-
plexes (HGG < GHG ≤ GGH [51,52]), however the different structural 
preferences of the two metal ions resulted in different stability order in 
the present case. The ATCUN-related GGH (L3) is the weakest (η5-Cp*) 
Rh(III) binder (Table 1), since only three binding sites of Rh(III) half- 
sandwich cation are available, in a facial geometry. On the other 
hand, histidine-amide (L4) and HGG (L5) provide tridentate facial {NH2, 
Nim,N− } coordination, therefore these ligands have considerably higher 
(η5-Cp*)Rh(III) binding affinity. Interestingly, GHG-NH2 (L6) is the 
strongest (η5-Cp*)Rh(III) binder, despite its preference for meridional 
Fig. 7. Parts of TOCSY (A) and NOESY (B) spectra of the (η5-Cp*)Rh(III)-L6 1:1 
system at pH 4.43. 
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geometry. 
Having explored the binary (η5-Cp*)Rh(III)-peptide complexes, we 
also studied some (η5-Cp*)Rh(III)-A-B ternary systems (where A = L2, 
L3, L4, L5 or L6; B = 2,2′-bipyridyl (bpy) or ethylene-diamine (en)), in 
order to mimic the interaction of the (η5-Cp*)Rh(III)-based potentially 
anticancer or drug delivery agents with proteins. Although, the [Ru(II) 
(p-cymene)(en)Cl]PF6 and [(η6-biphenyl)Ru(II)(en)Cl]PF6 compounds 
[3], as well as (η5-Cp*)Rh(III) complexes of some (N,N) polypyridyl li-
gands showed promising in vitro antiproliferative activity [16], the (η5- 
Cp*)Rh(III) complexes of en and bpy possessed negligible effect. 
Nevertheless, we selected these simple ligands, as they have high and 
already studied binding affinity to (η5-Cp*)Rh(III) [53]. Their pM* 
values calculated under the conditions given in Table 1 are pM* = 12.65 
(en) and 13.90 (bpy). 
The ternary systems were studied by 1H NMR spectroscopy, which 
allowed the estimation of the amount of both bound and unbound 
peptides, as well as en/bpy ligands. The 1H NMR spectra were recorded 
24–36 h after the solution preparation, and were then stable by time. 
Our data (Fig. S16) indicated that the weakest binder GGA-OH does not 
interact with the (η5-Cp*)Rh(III)-bpy/en complexes. However, all his-
tidine containing peptides form ternary species with these bidentate li-
gands (Table 2). The NOESY spectra (Fig. S17) indicate that in all 
ternary complexes only the C2H and C5H protons of imidazole rings are 
in spatial proximity to the Cp*-methyl protons, i.e. in the ternary species 
these peptides coordinate monodentately to Rh(III) through their 
imidazole N1‑nitrogens. These observations also confirm, that consid-
ering only monodentate coordination at neutral pH the imidazole ring 
has much higher (η5-Cp*)Rh(III) binding ability than carboxylate or 
amino groups. Moreover, in the cases of L4, L5 and L6 even the signals of 
binary peptide complexes appeared on the NMR spectra (Fig. S16), i.e. 
these peptides are able to displace these strongly coordinating bidentate 
ligands (en or bpy) from the coordination sphere of (η5-Cp*)Rh(III). 
Although the data in Table 2 broadly reflect the thermodynamic stability 
of binary complexes, the strongest (Cp*)Rh(III)-binder L6 is an excep-
tion, since less binary peptide complexes were detected in the ternary 
systems than expected based on the corresponding pM* values. Due to 
the unknown values of N-terminal amino pKs of imidazole coordinated 
peptides, the correct evaluation of data in Table 2 is not possible. 
Nevertheless, an estimation of log K = 4.5 ± 0.5 can be given for the 
monodentate imidazole coordination to the corresponding en/bpy 
complexes, i.e. [(η5-Cp*)Rh(ab)Cl] + HxL = [(η5-Cp*)Rh(ab)(HxL)] +
Cl− (where (ab) = en or bpy, L = L3, L4, L5 or L6, with either neutral (x =
0), or protonated (x = 1) amino group). This values is considerably 
higher than log K3 ~ 3 obtained in the (η5-Cp*)Rh(III)-L1(m) systems 
(Table 1), indicating some additional interaction(s), which seems to be 
necessary for efficient binding of [(η5-Cp*)Rh(ab)] cation to imidazole 
sidechains of proteins under submilimolar conditions. 
2.7. Geometry optimization and stereoisomerism 
Although, the (η5-Cp*)Rh(III) cation is known to form “chiral-at- 
metal” complexes, the presence of two diastereomers on the NMR 
spectra was detected only in the (η5-Cp*)Rh(III)-L6 system. In the other 
cases, either only one of the two possible diastereomers is formed, or 
their epimerisation is fast. In order to study this behaviour and to 
determine the most probable solution structures of peptide complexes 
present at near physiological pH (MH− 1L), we performed a computa-
tional study using combined molecular mechanical and density func-
tional methods. Applying the Macromodel program and the OPLS3e 
force field [54] we generated numerous different conformations for each 
monomer complexes which satisfied the geometrical constraints for the 
metal-binding sites and the proton-proton proximities obtained from the 
NMR study. The geometry for the best ranked conformations obtained in 
this way were then re-optimized at DFT/B3LYP-D3/6-31G(d,p)/LACVP 
level without any constraints using the Jaguar program [55] (see the 
Experimental section for the details). The final structures were selected 
(on energetic ground) from those ones that satisfied the NMR constraints 
even after optimization. Selected bond lengths and Cartesian co-
ordinates of the optimized structures are listed in Tables S1 and S2, 
respectively. The calculated Rh-N/Rh-Cl values are somewhat longer 
(0–0.06 Å for Rh–N, and 0.07–0.11 Å for Rh–Cl) than expected from 
the related crystal structures [42,56,57], however similar deviations 
were found in Ru(II) complexes using the DFT/B3LYP/6-31G(d,p)/ 
LANL2DZ method [58]. 
Bidentate {NH2,N− } coordination of a peptide to (η5-Cp*)Rh(III) 
allows fast epimerisation of the Rh(III) centre [34,59]. This agrees well 
with the nearly equal energies of the two optimized diastereomers for 
[MH− 1L2] (Fig. S18). On the other hand, tridentate coordination of L- 
amino acids with SαC absolute configuration results exclusively R 
configuration for the metal centre [35,38]. Accordingly, our calculation 
resulted stable structure only for the RRhSαC diastereomer (Fig. 4) in the 
case of histidine-amide ([MH− 1L4]+) and HGG-OH ([MH− 1L5]). 
In [MH− 1L3] the GGH-OH peptide has tridentate coordination, i.e. 
may give a single diastereomer. Although less likely, the 10-membered 
macrochelate may nonetheless allow the fast epimerisation. The opti-
mized structure of the two diastereomers (Figs. 4A and S18C) show 
rather strained macrochelates, which would likely prevent the rapid 
epimerisation. The SRhSαC diastereomer has more severely distorted 3H- 
amide group (the sum of the bond angles around the peptide nitrogen is 
353.6◦ vs. 357.3◦). More importantly, in the SRhSαC diastereomer the 
metal ion is far from the plane determined by the imidazole ring 
(Fig. S18C), which is highly unusual for imidazole complexes [60]. 
Consequently, the single set of NMR peaks for [MH− 1L3] is probably due 
to the solely presence of the energetically more stable RRhSαC 
diastereomer. 
In the case of [MH− 1L6]+ we observed two sets of NMR peaks, i.e. the 
presence of both diastereomers. The isomer ratio is c.a. 8:1, therefore 
proton-proton proximities could be determined only for the major dia-
stereomer. In this case, none of the optimized geometries could fulfil all 
NOESY constraints, therefore we neglected the Cp*-CH3-3H-NH prox-
imity constraint, since the 3H-NH proton is not part of the fused (5,6) 
chelate rings. The most stable structure obtained in this way was a 
RRhSαC diastereomer (Fig. 4D), as in all previous cases. Due to the lack of 
structural information on the minor isomers, we obtained several 
possible geometries with nearly equal energies (Fig. S18D). However, all 
of them have at least 3.6 kcal/mol higher energy than the RRhSαC dia-
stereomer. Although, this energy difference corresponds to a much 
higher excess of major RRhSαC diastereomer, we should emphasize, that 
our calculation was performed in implicit water environment, which 
cannot completely mimic the presence of a real solvent. 
A single set of NMR peaks was detected for the dimer (MH− 1L3)2 
species, too. Discarding the possibility of fast epimerisation, this 
observation indicates that either the RRhSαC/RRhSαC or SRhSαC/SRhSαC 
diastereomer is present in the solution. For these dimer complexes no 
Table 2 
Percentage of binary and ternary complexes in the (η5-Cp*)Rh(III)-L2–6-en/bpy 
1:1:1 ternary systems at pH 7.4.  
Ternary 
system 




binary complex of 
peptide (%) 
M-L2-en 100 – – 
M-L3-en 29 71 – 
M-L4-en 14 12 74 
M-L5-en – 15 85 
M-L6-en 28 34 38 
M-L2-bpy 100 – – 
M-L3-bpy 25 75 – 
M-L4-bpy 30 62 8 
M-L5-bpy 27 62 11 
M-L6-bpy 28 72 –  
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conformational search was carried out due to their much higher 
conformational freedom as compared to the monomer complexes. 
Instead, we took two (either RRhSαC or SRhSαC) optimized monomer ge-
ometries and connected them by imidazole coordination to obtain a 
relatively symmetric dimer structure. These initial geometries were 
minimized with the same DFT (Density Functional Theory) method as in 
the case of monomers (Fig. S19, for Cartesian coordinates see Table S2). 
In this case, too, the complex with R configuration around the metal ions 
(RRhSαC/RRhSαC diastereomer) resulted in lower energy, thus probably 
this isomer is present in the solution. 
3. Conclusions 
Our goal was to explore the possible interactions of potential met-
allodrugs ((η5-Cp*)Rh(III) complexes) and biomolecules (peptides/pro-
teins), in order to understand the most important thermodynamic 
factors influencing the biospeciation and biotransformation of (η5-Cp*) 
Rh(III) complexes. As the imidazole ring of histidine side-chains is one of 
the main binding sites for (arene)Ru(II)/Rh(III) cations in proteines, first 
we performed systematic solution thermodynamic, solution structural 
and computational study on the binary complexes of (η5-Cp*)Rh(III) 
cation with histidine containing peptides and their constituents. The 
comparative evaluation of our solution chemical (pH-potentiometry, 
UV–Vis, 1H NMR, ESI-MS) data indicated that all the seven studied li-
gands form highly stable complexes with (η5-Cp*)Rh(III) cation, which 
is able to induce the deprotonation of amide nitrogen well below pH 7. 
Consequently, around the physiological pH the peptide ligands are co-
ordinated to Rh(III) by a tridentate (for L2 bidentate) manner, with the 
participation of amide nitrogen. These observations indicate, that if 
thermodynamically stable 5/6-membered chelate ring may form with a 
suitable anchoring (amino or imidazole) group, amide nitrogen is indeed 
a potential binding site for (η5-Cp*)Rh(III) in neutral aqueous solution. 
The calculated pM* values (Table 1), which directly related to the (η5- 
Cp*)Rh(III) binding affinity, reflect the following order of thermody-
namic stability at pH 7.4: L1 ~ L1m < < L2 < < L3 < < L4 < L5 < L6. 
Consequently, the observed binding strength essentially depends on the 
presence and position of histidine unit within the peptide sequence. The 
ATCUN-motif related GGH-OH (L3) is the weakest (η5-Cp*)Rh(III) 
binder, since its tetradentate nature does not fit to the three available 
(facial) binding sites of (η5-Cp*)Rh(III). On the other hand, histidine- 
amide (L4) and HGG-OH (L5) binds considerably stronger to (η5-Cp*) 
Rh(III) due to their tridentate facial {N3im,NH2,N− } binding sites. Sur-
prisingly, GHG-NH2 (L6) was found the strongest (η5-Cp*)Rh(III) binder, 
despite its preference for meridional coordination geometry. 
Based on density functional theory calculations, we also suggested 
solution structures for all peptide complexes present at near physio-
logical pH. In the cases of tridentately coordinated histidine peptides, 
the R configuration around the metal ion resulted in the lowest energies. 
Having explored the binary (η5-Cp*)Rh(III)-peptide complexes, we 
also studied the (η5-Cp*)Rh(III)-peptide-B ternary systems (where B =
2,2′-bipyridyl or ethylenediamine) in order to mimic the interaction of 
the (η5-Cp*)Rh(III)-based potentially anticancer or drug delivery agents 
with proteins. At pH 7.4, all histidine containing ligands form ternary 
species with (η5-Cp*)Rh(III) complexes of strongly coordinating biden-
tate (N,N) ligands (ethylene-diamine (en) and bipyridyl (bpy)). In these 
ternary complexes the peptides are monodentately coordinated to Rh 
(III) through their imidazole N1‑nitrogens, i.e. at physiological pH the 
monodentate imidazole coordination (log K = 4.5 ± 0.5) provides 
considerably higher thermodynamic stability than either carboxylate or 
amino groups. Moreover, in the cases of L4, L5 and L6 the signals of 
binary peptide complexes were also present on the NMR spectra of 
ternary systems, indicating that histidine peptides are able to displace 
these powerful bidentate ligands (en or bpy) from the coordination 
sphere of metal ion. These behaviours may have important implication 
on the biospeciation/ biotransformation of (η5-Cp*)Rh(III) and related 
half-sandwich complexes in human bodies. 
4. Experimental section 
4.1. Materials 
All reagents were of analytical grade and used without further pu-
rification. KCl, HCl, KOH, 1-methylimidazole (L1m, 99%), GGA-OH (L2, 
98%), GGH-OH (L3, 98%), HGG-OH (L5) were purchased from Sigma- 
Aldrich, histidine-amide (L4, 99%) from Bachem AG, imidazole (L1, 
99%) from Alfa Aesar, while GHG-NH2 (L6) was prepared in our labo-
ratory. The (Cp*)Rh(III) stock solution was prepared from [(Cp*)RhIII(μ- 
Cl)Cl]2 (Sigma-Aldrich, 97%), and was standardized by acid-base 
titrations. 
4.2. Synthesis of GHG-NH2 (L6) 
GHG-NH2 peptide (L6) was synthesized on an Fmoc-Rink Amide AM 
resin (100–200 mesh, 0.71 mmol/g, 0,704 g = 0.5 mmol), using the 
standard solid phase synthesis protocol with Fmoc-chemistry (Fmoc =
Fluorenylmethyloxycarbonyl protecting group). Coupling was per-
formed with DIC (N,N′-Diisopropyl-carbodiimide)/HOBt (Hydrox-
ybenzotriazole) as activating agents, in DMF (Dimethylformamide) with 
a threefold excess of reagents. After each coupling, Kaiser (ninhydrin) 
test was performed to check the coupling efficiency. Deprotection was 
performed with a piperidine/DMF, 1:4 (v/v) mixture. After the last 
deprotection step, 93% TFA (trifluoroacetic acid), a mixture of 2.5% 
H2O, 2.5% TIS (triisopropylsilane), and 2% DTT (dithiothreitol) was 
used for the cleavage for 3 h at 0 ◦C. After the removal of TFA, the 
peptide was precipitated with cold diethyl ether, filtered, washed again 
with diethyl ether, dissolved in 50% aqueous acetic acid, and lyophi-
lized. The crude peptide (yield: 86.6%) was purified using a Phenom-
enex Jupiter C18 column with a gradient of H2O:ACN (acetonitrile) 
100:0 v/v to H2O:ACN 70:30 v/v in a presence of 0.1% TFA at a flow rate 
of 3 cm3/min and with a gradient of 0.5% ACN/min. Purity control was 
done by analytical HPLC (Fig. S20A), by High-Resolution ESI-MS spec-
trometry on a Q Exactive Plus hybrid quadrupole-orbitrap mass spec-
trometer (Thermo Scientific, Waltham, MA, USA) in a positive ion mode 
(m/z calcd for C10H16N6O3 [M + H]+ 269.13566, found 269.13568, 
Fig. S20B), and by 1H NMR (500 MHz, 10% D2O/H2O, pH 1.65, δ (ppm): 
3.17 (m, 2H, 2H–CβH2), 3.76 (m, 2H, G-CH2), 3.84 (d, 2H, G-CH2), 7.23 
(d, 2H, J = 232.5 Hz, C(O)-NH2), 7.24 (s, 1H, C5–H), 7.94 (br, 1H, 3G-C 
(O)-NH), 8.52 (s, 1H, C2–H), 8.75 (s, 1H, 2H-C(O)-NH), Fig. S20C). 
4.3. Potentiometric measurements 
The protonation and coordination equilibria were investigated by 
potentiometric titrations in aqueous solution (I = 0.2 M KCl, and T =
298.0 ± 0.1 K) under Ar using an automatic titration set including a 
computer controlled Dosimat 665 (Metrohm) autoburette and an Orion 
710A precision digital pH-meter. The titrations were performed with 
carbonate-free KOH solution (0.10 M, I = 0.2 M (KCl)). The Metrohm 
Micro pH glass electrode (125 mm, type 6.0234.100) was calibrated 
[61] via the modified Nernst Eq. (1): 




where JH and JOH are fitting parameters in acidic and alkaline media for 
the correction of experimental errors, mainly due to the liquid junction 
and to the alkaline and acidic errors of the glass electrode; Kw = 10–13.76 
M2 is the auto-ionization constant of water. The parameters were 
calculated by the non-linear least squares method. The hydrolysis con-
stants for [((Cp*)RhIII)2(OH)n]4-n complexes, where n = 2 or 3, deter-
mined in our laboratory (log β2–20 = − 11.01(1), log β2–30 = − 18.94(2)) 
agree well with the literature data [62]. The complex formation was 
described by a general equilibrium process as follows: 
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pM + qH + rL ↔









where M denotes the metal ion, L the non-protonated ligand molecule, 
and H stands for protons. The corresponding formation constants 
(βMpHqLr ≡ βpqr) were calculated using the PSEQUAD computer program 
[63]. 
The protonation constants were determined from four independent 
titrations (50–60 data points per titration), with ligand concentration 
1.0–6.0 × 10− 3 M. The complex formation constants were evaluated 
from 4 to 7 independent titrations (60–70 data points per titration). The 
metal-to-ligand ratios were 6:1, 3:1, 2:1, and 1:1. The metal ion con-
centrations varied between 1.0 and 1.5 × 10− 3 M, depending on the 
metal-to-ligand ratio. The titrations were performed between pH 1.9 and 
11.5. pH equilibrium was assumed to be reached if a change in the 
measured potential was equal or less than 0.2 mV within 2 min. The 
average waiting time between two doses of titrant solution was 4–6 min 
up to pH 6, which increased to 6–30 min between pH 6–8 (in this pH 
region, the (Cp*)Rh(III)-GGH-OH (L3) system was the slowest, which 
needed 20–30 min for pH equilibration). Above pH 8 the equilibration 
was still relatively fast (6–10 min waiting time) in the (Cp*)Rh(III)-1- 
methylimidazole (L1) and (Cp*)Rh(III)-GGA-OH (L2) systems, but the 
maximal waiting time (30 min) was not enough to attain the pH- 
equilibrium in the other systems. In these cases, the measured data 
were evaluated separately, and used only as indicative information (see 
values in square brackets in Table 1). 
4.4. UV–Vis, NMR and ESI-MS measurements 
UV–Vis spectra were measured on Thermo Scientific Evolution 200 
spectrophotometer using a cell with 2, 1 and 0.5 cm optical pathlengths. 
The individual UV–Vis spectra of the complexes were calculated by 
PSEQUAD computer program [63]. The pH-dependent spectrophoto-
metric titrations were performed at 1:1 metal-to-ligand ratio, with 
[(Cp*)RhIII]2+ concentration of 0.15–0.30 mM, over the pH range 
1.9–11.5 at an ionic strength of 0.20 M (KCl) and at T = 298.0 ± 0.1 K. 
1H NMR studies were carried out on a Bruker Ultrashield 500 Plus in-
strument. The ligands were dissolved in a 10% (v/v) D2O/H2O mixture 
to yield a concentration of 1–2 mM, and the desired pH was adjusted by 
HCl/KOH solution at 298.0 ± 0.1 K and at I = 0.20 M KCl, in the absence 
or presence of [(Cp*)RhIIICl3] at 1:1, 2:3 or 1:4 metal-to-ligand ratios. 
The chemical shifts (δ) were measured relative to methanol as internal 
reference and converted to SiMe4 reference using δmethanol = 3.35. Data 
were processed using the Topspin 2.0 software package (Bruker). High 
resolution MS spectra were recorded using aqueous solutions without 
background electrolyte on a Q Exactive Plus hybrid quadrupole-orbitrap 
mass spectrometer (Thermo Scientific, Waltham, MA, USA) equipped 
with a heated electrospray ionization (HESI-II) probe that was used in 
the positive mode, which was coupled to an Abi 140C Syringe Pump. 
4.5. Density functional theory calculations 
Initial conformations were generated for each of the investigated 
systems using OPLS3e force-field [55] and a torsional/low-mode sam-
pling method as it is implemented in the Macromodel program of the 
Schrödinger package [64]. 1000 conformations were generated using 
the distance constraints derived from the NOESY data. The five highest 
ranked arrangements were selected for density functional theory ge-
ometry optimization. This unconstrained minimization was carried out 
in two subsequent steps. First the total energy was minimized in vacuum 
using the B3LYP-D3 [65–67] functional and the 6-31G basis set [68]. For 
the Rh(III) ion LACVP basis set [69] with effective core potential was 
applied that also includes relativistic corrections. The geometry 
obtained this way was further optimized with the help of the same 
functional, but the basis set was enhanced adding polarization functions 
to it (6-31G(d,p) [70]). The solvent effects were taken into account 
employing the polarized continuum model, PCM. The conformations 
with the lowest total energy fulfilling the NOESY constraints were 
selected as final structure for each investigated system. For DFT calcu-
lations we used the Jaguar program from the Schrödinger package [55] . 
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